The Promise of Emerging Therapies for Patients with Desmoid Tumors
Speakers: Richard Riedel, MD, Associate Professor of Medicine with TenureMrinal Gounder, MD, Associate Attending Professor
Duration: 60 minutes
Presented on: December 12, 2023
Richard Riedel, MD
Richard Riedel, MD
Associate Professor of Medicine with TenureRichard F. Riedel, MD is an associate professor with tenure in the Division of Medical Oncology at Duke University Medical Center in Durham, NC. He is the associate director for clinical and translational research in the Duke Sarcoma Center and is the program director for the Duke Hematology-Oncology Fellowship program. Dr. Riedel’s research focuses on identifying novel therapeutics for patients with soft tissue and bone sarcoma. He is an active participant in Sarcoma Alliance for Research through Collaboration (SARC) and is a member of the American Society of Clinical Oncology (ASCO), the Connective Tissue Oncology Society (CTOS), and the National Comprehensive Cancer Network (NCCN) guideline committees for both soft tissue sarcoma and GIST.
Mrinal Gounder, MD
Mrinal Gounder, MD
Associate Attending ProfessorMrinal Gounder, MD is an internationally recognized medical oncologist and investigator who holds dual appointments in the sarcoma and early drug development programs at Memorial Sloan Kettering Cancer Center (MSKCC). He specializes in developing new drugs across solid tumors, with a specific focus on sarcomas and rare cancers. He has served as principal investigator of several practice-changing global clinical trials and his original research has been published in numerous peer-reviewed journals. His research contributions in rare cancers were recognized as one of the Top 10 Advances of the Year in 2018 by the American Society of Clinical Oncology. As the MSKCC Physician Ambassador to India and Asia and he is leading efforts to build cancer care networks to improve access to patient care, education, graduate medical training, and advanced cancer research and clinical trials.
The Promise of Emerging Therapies for Patients with Desmoid TumorsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Organization for Rare Disorders (NORD) and the Desmoid Tumor Research Foundation (DTRF)
ACKNOWLEDGEMENTThis activity is supported by an independent educational grant from SpringWorks Therapeutics, Inc.
DATE OF RELEASE/EXPIRATIONThis activity was released on December 12, 2023 and is valid for 12 months. Requests for credit must be made no later than December 12, 2024.
TARGET AUDIENCEThe educational design of this activity addresses the needs of sarcoma specialists, medical oncologists, and other members of the care team for desmoid tumors.
STATEMENT OF NEED/PROGRAM OVERVIEWDesmoid tumors are challenging to manage due to the difficulty obtaining an accurate diagnosis and the scarcity of treatment options. Despite the benefits seen with tyrosine kinase inhibitors, there are no FDA-approved therapies yet for treatment of desmoid tumors. However, emerging therapies are showing clinical benefit and have the potential to improve the treatment armamentarium.
Join a panel of experts to discuss the best strategies to improve timely diagnoses of patients with desmoid tumors. Experts will review the recent shift away from extensive surgery to active surveillance and explore emerging treatments that have demonstrated promising results for patients with progressive disease. Panelists will also discuss the need for multidisciplinary review to determine if treatment is warranted and examine which patients are eligible for treatment with emerging options
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Apply relevant strategies to address timely diagnosis in patients with desmoid tumors
- Discuss patient selection for treatment based on safety and efficacy data
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPSGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Mrinal Gounder, MD
Associate Attending Professor
Sarcoma Oncologist & Early Phase Drug Development Specialist
Memorial Sloan Kettering Cancer Center
Consulting Fee (e.g., Advisory Board): Ayala Therapeutics, Aadi Biosciences, Rain Oncology, Epizyme, Regeneron, Boehringer Engelheim, Bayer
Contracted Research (Principal Investigators must provide information, even if received by the institution): Ayala Therapeutics, Aadi Biosciences, Bayer, Boehringer Ingelheim, Epizyme, Springworks, Rain Oncology
Richard F. Riedel, MD
Associate Professor of Medicine with Tenure
Associate Director, Duke Sarcoma Center
Duke Cancer Institute
Consulting Fee (e.g., Advisory Board): AADi, Adaptimmune, Blueprint, Boehringer Ingelheim, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, NanoCarrier, SpringWorks
Contracted Research (Principal Investigators must provide information, even if received by the institution): AADi, AROG, Ayala, BioAtla, Blueprint, Cogent, Daiichi-Sankyo, Deciphera, GlaxoSmithKline, InhibRx, NanoCarrier, Oncternal, PTC Therapeutics, SARC, SpringWorks, Tracon, Trillium
Desmoid Tumor Patient
Nothing to disclose
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accreditation Support:For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org
Technical Support:For any technical issues or issues with your CME Certificate, please contact, OMedLive, at 877-394-1306 or at Support@OMedLive.com.